The Art & Science of Wellness
SUZHOU, China, Jan. 29, 2019 /PRNewswire/ — CStone Pharmaceuticals (CStone) today announced that the National Medical Products Administration (NMPA) recently approved the clinical trial application (CTA) to start a Phase…
SHANGHAI, Jan. 28, 2019 /PRNewswire/ — I-Mab Biopharma (“I-Mab”), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, announces on…
TORONTO, Jan. 26, 2019 /PRNewswire/ — Gratomic Inc. (the “Company”) (TSX.V:GRAT), a publicly traded Canadian TSX.V company, and TODAQ Holdings Inc. (“TODAQ”) are pleased to announce that they have entered…
CHENNAI, India, Jan. 25, 2019 /PRNewswire/ — Apollo Hospitals Enterprise Ltd. (BSE: 508869) (NSE: APOLLOHOSP), India’s first multi-speciality chain of hospitals, today opened the Apollo Proton Cancer Centre (APCC), giving…
REYKJAVIK, Iceland, Jan. 25, 2019 /PRNewswire/ — A whole genome sequence-based portrait of how the two basic mechanisms generating human diversity work Elucidates how women and men contribute differently to…
PLYMOUTH MEETING, Pennsylvania, Jan. 24, 2019 /PRNewswire/ — Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that a second patient with HPV-related head and neck cancer treated with INO-3112 (now called…
DARMSTADT, Germany, Jan. 24, 2019 /PRNewswire/ — Not intended for UK- or US-based media Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications…
-“Bo’ai Xin’an – Patient Benefit Management Program for breast cancer patients” was launched in Shanghai SHANGHAI, Jan. 23, 2019 /PRNewswire/ — Led by the Shanghai Branch of PICC Health Insurance…
Appointment Solidifies Strong Additives Positioning, Enhanced by Backward Integration SCHENECTADY, New York, Jan. 24, 2019 /PRNewswire/ — SI Group, a leading global developer and manufacturer of performance additives, process solutions,…
SHANGHAI, Jan. 22, 2019 /PRNewswire/ — I-Mab Biopharma (“I-Mab”), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, announced on…
Multilingual WordPress with WPML